The future of health, wellbeing and sustainability
By Jonathon Porritt - 12 February 10:43

Any take on sustainability that doesn’t have health and social care close to its heart probably isn’t worth taking seriously.

New Statesman
Covering up abuse: How Winterbourne View happened again
By Alan White - 02 October 12:50

“These aren’t isolated instances. It’s cultural, and it’s grown out of what’s happened in the care sector."

NICE snubs Roche’s new breast cancer drug
By Heidi Vella - 07 August 16:19

The UK's health cost watchdog, the National Institute for Care and Excellence, has rejected Roche's newest cancer drug Perjeta - the seventh such cancer drug to be by NICE since 2011.

New Statesman
When will big Pharma finally go transparent?
By Heidi Vella - 31 July 10:42

Not quite there yet.

Don't stop donating blood just because the government's sold the plasma service
By Alex Hern - 19 July 9:15

The company doesn't have anything to do with UK donor blood.

Medical futurology is no excuse for the UK's organ failures
By Michael Brooks - 18 July 8:51

A mouse with a human liver is extraordinary indeed, but we should do better with what science has provided.

New Statesman
Serco's troubles spread to the US
By Alex Hern - 17 July 9:07

The company is facing questioning over an Obamacare contract thanks to its problems in the UK.

NHS report author says claim of "13,000 needless deaths" is a misrepresentation
By George Eaton - 16 July 10:40

Bruce Keogh, the author of the report into 14 NHS trusts, writes: "Don’t believe everything you read, particularly in some newspapers."

Why is science doing so poorly in the fight against cancer?
By Michael Brooks - 20 June 11:07

We all know that doing the same thing over and over again and expecting the outcome to change is a mark of insanity. It's time for some fresh ideas on cancer research.

We should be able to sue the NHS
By Ed Fletcher - 17 June 7:43

This culture of secrecy and gagging orders needs to be changed.

E-cigarettes: the conspiracy theorists might just have it right
By Fred Crawley - 13 June 12:08

What’s really going on behind these clouds of nicotine-infused vapour?

"The tail’s wagging the dog": How outsourcing is eroding NHS services
By Alan White - 15 April 8:34

The battle over outsourcing for Suffolk’s community health services in Sudbury is a warning for the rest of the country - the future of the NHS is going to be fragmented.

Nurses dancing at Danny Boyle's Olympics opening ceremony
We are in danger of loving the NHS to death
By Nelson Jones - 21 February 12:30

Universal healthcare is the least citizens should expect. To make the NHS better for patients, politicians, press and public alike need to cultivate a healthly scepticism towards it, not give it unlimited adulation.

"Innovation" is an NHS buzzword. It shouldn't be.
By Martha Gill - 25 July 8:51

Martha Gill's Irrational Animals column.

Can Osborne really take credit for Glaxo's move?
By George Eaton - 22 March 12:13

It was a 2009 Labour announcement, not Osborne's Budget, that persuaded Glaxo to invest.

Sanofi to buy Pluromed
By New Statesman - 16 March 9:15

The French drug-maker to expand its presence in the biosurgery field.

UK activists block last sea transport for lab animals
By Andrew McIntyre - 14 March 11:44

Only foreign airlines can now transport live laboratory animals into Britain.

Doctors to direct patients to smartphone apps
By Andrew McIntyre - 22 February 11:54

GPs will be soon prescribing applications that allow patients to self-monitor their health.

Two and a half cheers for Bill Gates
By Anonymous - 03 February 10:57

To tackle neglected tropical diseases we need a far more collaborative and flexible approach.

Bill Gates
Two and a half cheers for Bill Gates
By Dr Mark Booth - 03 February 9:57

To tackle neglected tropical diseases we need a far more collaborative and flexible approach.

R&D News: High fructose consumption may put adolescents at cardiovascular risk
By NS Admin - 25 January 13:57

An analysis of 559 adolescents age 14-18 correlated high-fructose diets with higher blood pressure, fasting glucose, insulin resistance and inflammatory factors that contribute to heart and vascular disease.

Could pseudo-science fund cancer research?
By Mark Stevenson - 12 January 11:36

The geeks are on the march with increasingly vocal and co-ordinated calls for an end to crystal heal

The precarity of the global 99%
By Simon Reid-Henry - 24 November 16:07

What The Global Fund's decision to cancel next year's funding round means for victims of Aids, TB an

Google fined $500m for illegal advertising
By Sophie FitzMaurice - 25 August 14:00

The US-based multinational corporation was profiting from the illegal sale of drugs from Canada.

GMC pushes ahead with secret doctors' courts plan
By Andrew Pugh - 13 June 17:21

Plans to hold some misconduct hearings in private look set to go ahead.

Fat profits for Big Pharma
By Michael Barrett - 03 June 11:08

Can medicines treat obesity? When, in 1994, loss of a single gene encoding a protein hormone called leptin was shown to cause mice to balloon to five times their normal size, optimism was high.

The drugs don’t work
By Michael Barrett - 20 April 14:00

Pfizer's decision this year to close its research facility in Sandwich, Kent, surprised few who had been following the slump in the pharmaceutical industry.